Since thrombin cleaves fibrinopeptides A (FPA) and B from the NH 2 -terminal end of the fibrinogen molecule, measurement of fibrinopeptide levels in plasma may provide a direct index of thrombin action. Recently a radioimmunoassay for FPA has been developed, and in the present paper, we describe the application of this assay to the measurement of FPA levels in clinical blood samples. Since fibrinogen cross-reacts with antibodies to FPA, dialysis was used to extract the peptide from plasma. In vitro generation of FPA was prevented by removing the fibrinogen from the plasma by precipitation with ethanol before dialysis. The processing technique permitted recovery of 75% of FPA added to blood in vitro. Evidence that the immunoreactivity measured in plasma is due to FPA was provided by the results of experiments in which two antisera to FPA with different specificities showed comparable results and addition of thrombin caused no change in immunoreactivity. In contrast, extracts of streptokinasetreated plasma showed a five-fold increase in activity when treated with thrombin and markedly different immunoreactivity with the two antisera.
INTRODUCTION
During the past decade, a number of new tests have been developed to assist in the diagnosis and investigation of the pathophysiology of intravascular coagulation. Some of these tests depend on measurements of residual fibrinogen in serum derived from blood clotted by thrombin in vitro (1) . Such tests cannot be specific either for thrombin or for plasmin action in vivo, and may actually reflect the action of either or both of these enzymes (2) . Thrombin action on fibrinogen involves limited proteolysis, resulting in the production of fibrin monomer and the fibrinopeptides A and B. A number of attempts have been made to develop tests for thrombin action in vivo based on the detection of fibrin monomer (3) (4) (5) . In the present study, assay of fibrinopeptide A (FPA)1 was used as a technique for studying thrombin action in vivo. Thrombin cleaves arginyl-glycine bonds to release FPA (16 amino acids) from the NH2-terminal segment of the Aa chain and fibrinopeptide B (14 amino acids) from the NH2-terminal segment of the BP chain (6) . Thrombin-susceptible bonds are not cleaved by plasmin (7) , and hence it seemed possible that measurement of the fibrinopeptides might distinguish the action of thrombin from that of plasmin. Teger-Nilsson (8) was able to demonstrate the presence of fibrinopeptides A and B by chemical methods in the blood of dogs infused with sufficient thrombin to render the blood incoagulable. Since thrombin cleaves the A peptide before the B peptide (6), initial efforts have been focused on measuring the A peptide by the radioimmunoassay technique (9) . In the present paper, the application of this assay to clinical blood samples is described. The assay technique was modified to improve the sensitivity lAbbreviation used in this paper: FPA, fibrinopeptide A.
The Journal of Clinical Investigation Volume 54 July 1974 43-53of the assay, methods for extracting FPA from plasma were developed, and samples of blood were studied from a number of patients with elevated FPA levels. Immunochemical evidence for the specificity of the assay was obtained, and the in vivo clearance rate of FPA determined. The results of these studies are reported below.
METHODS
Reagents. Native FPA was prepared from fibrinogen (grade L, 95% clottable, from A. B. Kabi, Stockholm) as described by Bl6mback, Bl6mback, Edman, and Hessel (10) . Synthetic FPA was synthesized by the solid phase method of Merrifield (11) Antisera. The albumin-peptide conjugate was dissolved in 0.1 M saline at a concentration of 2 mg/ml and thoroughly mixed with an equal volume of complete Freund's adjuvant in a 2-ml glass syringe until it had thickened. White New Zealand rabbits were injected with the mixture on the following schedule: 0.6 ml into the toe pads at 1 wk intervals for a total of three injections, then 0.4 ml intramuscularly in the haunches at intervals of 2 wk. Specific binding of radiolabeled tyrosinated A peptide by the antisera resulted after 3 mo immunization. Antiserum (R55) to fibrinogen was a gift from Dr. C. Merskey, Albert Einstein College of Medicine, New York.
Radioimmunoassay. Tyrosinated peptide used in the present study was prepared by coupling tyrosine to aminoterminal alanine of synthetic A peptide in a 1:1 M ratio with the use of the ONP ester method (14) as previously described (9) . Tyrosinated FPA was radiolabeled with '25I by the chloramine-T method of Hunter and Greenwood (15) . The (20 mg/ml) was an equally satisfactory reagent. These reagents also increased the recovery of radiolabeled peptide. The iodinated peptide was separated on a Sephadex G 10 column as previously described (9) . The incorporation of isotope into tyrosinated peptide varied from 10-25%. Up to 80% of the radioactivity could be bound by the two antisera. The radioimmunoassay technique was modified from that previously described (9) to increase sensitivity. Dilutions were made in 0. 10 In method C, the processing of the plasma was varied so that the final extract contained FPA at a concentration equal to that of the original plasma. This technique was used only in the experiments in which the influence of heparin infusion was studied on the FPA level in normal individuals. 8 ml anhydrous ethanol was added to 2 ml plasma in 12-ml conical glass centrifuge tubes. After 30 min incubation at 40C, the tubes were centrifuged at 1,500 g for 20 min, and the top 5.5 ml from each of duplicate centrifuge tubes was pooled, incubated at 4VC for a further 30 min and then centrifuged at 1,500 g for 20 min. The top 10 ml was pipetted into a 16 X 100-mm glass tube, and the ethanol was evaporated by blowing a stream of nitrogen gas over the surface of the samples at 40'C. The dried extracts were reconstituted with 1.33 ml distilled water and 2.66 ml Tris-buffered saline, pH 8.6. The ionic strength of the reconstituted solution was 0.15 M. Heparin in vitro did not influence the radioimmunoassay technique. When the reproducibility of the assay was tested by doing 10 replicate determinations on a single sample of blood, the coefficient of variation was 25%o.
In vitro behavior of FPA immunoreactivity derived from the blood of patients with elevated FPA levels. Antiserum binding of FPA derived from two patients' plasma samples was tested as follows: 2 ml of the patients' plasma was processed by method A. The dialysate was divided into two equal-volume aliquots; 100 ,ul of a 1/10 dilution of R2 serum was added to one, and to the other, 100 Al buffered saline was added. 2 ml of each of the two filtrates was then dialyzed for 24 h against 8 ml Tris-buffered saline, pH 8.6, with 1 mg/ml ovalbumin. The final dialysates were then assayed for EPA activity. The gel filtration behavior of FPA extracted from a patient's blood was tested as follows: 9 ml plasma from patient C. N. was dialysed against 90 ml 0.1 M NH4HCO3, pH 8.5, with 50 Ag ovalbumin/ml. After 24 h dialysis at 4VC, the dialysate was lyophilized and reconstituted in 4.5 ml distilled water. A 0.5-ml sample of the reconstituted dialysate containing about 7 ng FPA was then filtered over a Sephadex G 25 column, and the elution pattern of FPA was compared with that obtained when native FPA was filtered over the same column.
FPA generation in vitro. The rate of FPA formation in normal blood after sampling was tested as follows: a stopwatch was started as the blood entered the syringe, and after collection of the entire sample of blood required (24-36 ml), the needle was withdrawn from the vein and removed from the syringe. The blood in the syringe was mixed by inversion, and at fixed time intervals, 4.5 ml blood was added to 0.5 ml of a 0.15 M NaCl solution containing 500 U of heparin and 500 U of Trasylol. The plasma was then processed by method A, and the A peptide levels were measured.
Streptokinase treatment of plasma. After studies in which the concentration of streptokinase and the incubation period were varied, the following procedure, which resulted in maximal generation of FPA immunoreactivity, was used (this immunoreactivity is thought to result from the reaction of fragments of fibrinogen, which include FPA): 0.25 ml streptokinase (25,000 U) was added to 10 ml citrated (1 ml 4% trisodium citrate/9 ml blood) plasma. After 60 min incubation at 370C, 1 ml Trasylol (1,000 U) was added, and 2 ml plasma was processed by method A and assayed.
Estimation of the clearance rate of FPA from the circulation. The disappearance rate of FPA from the circulating blood was studied after infusion of a solution containing FPA. Sterile preparations of clot supernate containing both fibrinopeptides A and B were prepared as follows: 20 ml sterile water was added to a 200 mg sterile mixture of anti-hemophilic factor, fibrinogen, and salt obtained from E. R. Squibb & Sons, New York. The solution was distributed into three sterile 13 X 100 glass tubes with a sterile syringe. 16 U (0.032 ,ul) of human thrombin were added to each tube, which was incubated at room temperature for 3 h; then the thrombin was neutralized with 16 U of hirudin, and the mixture then frozen overnight at -40°C. The next day the sample was thawed, and the fibrin was deposited by centrifuging at 20,000 rpm for 30 min. The supernatant fluid was filtered through an XM50 Amicon ultrafiltration membrane (Amicon Corp., Lexington, Mass.), and 16 ml of filtrate was obtained. Radioimmunoassay of the filtrate showed a total amount of 1.2 mg EPA at a concentration of 75 ,ag/ml. The material was prepared with aseptic technique throughout, and sterility testing of the final solution showed no bacterial growth. The solution was stored in 1-ml aliquots at -400 until it was used. Samples of the solution containing 150-600 ,g FPA activity in 2-8 ml saline were injected into the connecting tubing of an intravenous saline infusion (20 gauge needle) in the left arm. A 19-gauge butterfly needle was dipped in a 20,000 U/ml heparin solution and inserted into a vein in the right arm. 4.5-ml volumes of blood were withdrawn via the butterfly needle at set intervals. In the intervals between sampling the blood, a saline solution with 2 U heparin/ml was run through the butterfly needle, and about 100 ml of fluid was infused during the 15- was sampled through the needle before and at intervals after infusion of 10,000 U of heparin.
Previously described methods were used for standard coagulation tests: the partial thromboplastin time and onestage prothrombin time tests were as previously described (17); fibrinogen was measured by the Ellis and Stransky (18) and Ratnoff and Menzie (19) methods. The thrombin time test was as previously described (20) , bovine thrombin being used. Serum was prepared and fibrinogen antigen measured by the tanned red cell hemagglutination inhibition test as described by Merskey, Lalezari, and Johnson (1).
RESULTS
Assay technique. With the radioimmunoassay technique initially described, 0.8 ng FPA could be measured with accuracy (50% displacement of binding) at a concentration of 8 ng/ml, and a concentration of 2 ng/ml (20% displacement of binding) could be detected. In the clinical studies, the radiolabeling technique was improved, preincubation was employed, and a larger volume of test solution tested. These modifications permitted accurate measurement of 0.4 ng FPA/ml of solution (50% inhibition of binding), and 0.15 ng/ml could be detected (Fig. 1) (Table II) . Grossly higher immunoreactivity levels were obtained when R33 antiserum was used than when R2 antiserum was used (Table II) . To define the meaning of 'the discrepancy, a series of experiments was made. Synthetic and native FPA and dialysates of thrombin-treated plasma showed equivalent immunoreactivity with both R2 and R33 antisera (Table III) . Thrombin treatment did not alter the activity of native or synthetic A peptide. On the other hand, dialysates derived from plasma treated with streptokinase showed a significant increase in reactivity when treated with thrombin (Table III) . Dialysates derived from streptokinase-treated plasma also showed significantly higher immunoreactivity when tested with the R33 antiserum than when tested with the R2 antiserum The following amounts of anticoagulants were used in a 1-ml vol/9 ml blood: Trasylol, 1,000 U; trisodium citrate, 0.14 mM; sodium oxalate, 1.3 mM; EDTA, 0.0134 mM; hirudin, 5 U. The results represent the mean of those derived from five separate experiments and indicate FPA immunoreactivity.
( Table III) . On the basis of these results, it was thought that the A peptide alone (Aa chain 1-16) gave similar results with the two antisera but that larger fragments of the fibrinogen molecule, such as would be cleaved by plasmin and which included FPA, gave relatively lower reactivity with R2 antiserum when thrombin in the antiserum was inhibited with hirudin. To substantiate this hypothesis, a series of fragments of the fibrinogen molecule were tested with the two antisera. These studies showed that the 16-amino acid A peptide gave the same immunoreactivity with the two antisera, whereas Aa chain fragment 1-51, the NH2-terminal disulfide )lasmin digestion of the supernate of the 50% ethanol precipitate was found molecule all showed to give the lowest FPA values (Table IV) . Such cona molar basis with centrations of ethanol (7.7% in the incubation mixture L2 antiserum.2 It was with antiserum) slightly inhibited binding in the assay fibrinogen (23) dur- (Table IV) , and an equivalent amount of ethanol was might be responsible therefore included in the standard fibrinopeptide inhiients of the Aa chain bition curve. Tests of the dialysate of the ethanol prenmunoreactivity with cipitate of plasma showed that the high levels of imLim. Accordingly, the munoreactivity detected by the R33 antiserum were revised to prevent present in the precipitate. When fibrinogen was first is, and the fibrinogen removed from plasma by ethanol precipitation and the ed with ethanol and plasma then dialysed, similar results with R2 and R33 normal plasma was antisera were obtained with a number of anticoagulant itrations of ethanol, mixtures, and heparin and Trasylol appeared to give similar results to heparin, hirudin, and Trasylol (Table  II) . Thrombin treatment of the dialysates did not increase the activity, suggesting that fragments of the 36-230 Aa chain larger than the A peptide were not present in significant amounts. Recovery of FPA added to plasma processed by ethanol precipitation and dialysis was -about 75% (Table I) . Recovery was similar whether the peptide was added to plasma or to anticoagulated whole blood. For all further studies, the plasma was first precipitated with 50% ethanol.
In a further experiment, the rate of generation of FPA in normal blood was studied by measuring FPA ____,___,___,_ levels in blood incubated in the collecting syringe for 6 7 8 9 various time periods before mixture with heparin and in)
Trasylol. The FPA concentration remained below 1 'mixed with heparin ng/ml for 3 min and began to rise steeply only after 7 od mxed ith epa m mi (Fig. 2) . als after sampling the s the time interval beClinical studies. FPA levels in 30 normal men ranged syringe and its mix-from 0.1 to 2 ng/ml with a mean of 0.50 ng/ml. Serial he results shown are FPA estimations in a patient with steady-state defibrina-;eparate experiments. tion (Kasabach-Merritt syndrome) showed levels rangNossel, and V. P. ing from 4.7 to 9.6 ng/ml with a mean of 6.2 ng/ml. iction between fibrinohe fibrinogen molecule On two occasions, after heparin infusion no FPA was iration.
detectable in the patient's plasma (Table V) . The pa-
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Nossel, Yudelman, Canfield, Butler, Spanondis, Wilner, and Qureshi tient, C. N., is a 20-yr-old girl with a congenital hemangioma of the right leg extending to the thigh and pelvis.
FPA levels in patients with overt defibrination varied between 4 and 290 ng/ml (Table VI) . FPA levels in several other patients without overt defibrination but with evidence of thrombosis or embolism varied between 5 and 23 ng/ml ( Table VII) . Evidence that the immunoreactivity found in the blood of the patients was FPA is provided by the quantitatively similar results obtained when the plasma extract was tested with the R2 and R33 antisera in the presence of hirudin or after thrombin treatment (Tables VI and VII) . In patient C. N., a plasma extract was eluted from a Sephadex G 25 column at approximately the same elution volume as FPA (Fig.  3) . FPA immunoreactivity derived from extracts of two patients' blood was bound in vitro by R2 antiserum and passage through a dialysis membrane was prevented.
FPA clearance in vivo. To interpret the quantitative significance of elevated FPA levels, native fibrinopeptide was infused into four individuals, and the rate of clearance from the circulation was measured. About 70% of the infused peptide was recovered in the recipients' plasma, and the initial rate of disappearance was equivalent to a ti of 3-5 min (Fig. 4) . After heparin infusion in a number of patients with elevated FPA, the level declined rapidly at a rate equivalent to a 3-5-min ti but usually remained at about 1-2 ng/ml over the first 15 min (Fig.  5) . Heparin The results of coagulation tests on the patient's blood were as follows: partial thromboplastin time, 88 s (control 54 s); prothrombin time, 32 s (control 13 s); thrombin time, > 180 s (control 16 s); fibrinogen level, 55 (45-65) mg 100 ml; prothrombin, 58%; factor V, 42%; factor VIII, 24%; factor IX, 58%; factor X, 64%; factor XI, 93%; factor XII, 76%; factor XIII decreased; euglobulin lysis time (with 2 mg/ml added fibrinogen), 2 h; platelet count 80-120,000/mm3; tanned red cell hemagglutination inhibition assay of nonclottable fibrinogen antigen, 10-20,gg/ml (normal 0-1 ug/ml).
A radiolabeled fibrinogen disappearance study was made in 1964 and showed an accelerated clearance rate (21 only slight reduction in FPA immunoreactivity measured with the R2 and R33 antisera (Table VIII) . DISCUSSION It is recognized that the plasma-processing technique used in the present study is cumbersome, but of the methods tried, it resulted in the most reproducible results. It is to be anticipated that more efficient methods for processing the plasma will be developed.
In interpreting the results obtained, evidence for the specificity of the FPA assay is derived from the results of a number of different experiments. Perhaps the strongest evidence for specificity is derived from the similar FPA levels found with both the R2 and R33 (Tables  II, VI, and VII) . Hence, the similar results found in plasma samples studied with these two antisera suggest that most of the immunoreactivity is due to the 16-amino acid FPA. The lack of increase in immunoreactivity resulting from thrombin treatment of the dialysates of plasma from which fibrinogen had been removed by precipitation with ethanol before dialysis (Tables III,   17T --17TTN As4A1 _ r-I1 _tA1__ responsible, one may consider which fragments of fibrinogen might be responsible for the immunoreactivity found. Two possible cleavage sites are between amino acids 23 and 24 and between 43 and 44 (7) . Cleavage of the 1-23 amino acid fragment is suspected because cleavage of the 43-44 bond would be expected to release a fragment containing beta, gamma, and alpha chains from the NH2-terminal end of the molecule. Such a segment of the fibrinogen molecule would have a molecular weight of about 50,000 and would not be dialysable through the dialysis tubing used here. In contrast, the streptokinase produced immunoreactivity has a dialysis rate indistinguishable from that of FPA. Hence the 1-23 amino acid peptide may be produced by plasmin action and cross-react in the assay. The increase in cross-reactivity of the dialysate from streptokinase-treated plasma on treatment with thrombin (Table III) is thought to be due to different conformations of the 1-16 and 1-23 amino acid peptides so that the antigenic determinant of the 1-16 amino acid peptide recognized by the R2 antiserum is partly hidden in the 1-23 amino acid peptide.'
It is important to know whether the FPA levels in plasma samples represent circulating FPA or FPA generated in vitro after the venipuncture. The relatively slow rate of FPA generation in blood in vitro (Fig. 2) is against the possibility that thrombin generated as a result of the venipuncture is responsible for the range of FPA levels found in clinical samples. Also indicating that it is circulating FPA which is being measured is the ordered rate of decline in FPA level at a rate equivalent to a ti of approximately 3-5 min after heparin infusion in patients with elevated FPA levels (Fig. 5) . If the heparin effect were that of preventing thrombin generation in response to the venipuncture, one would expect immediate maximal reduction in the FPA level after heparin infusion.
An important question concerns the significance of the FPA levels found in plasma. Although thrombin action on fibrinogen is the most likely cause of FPA production, other enzymes, such as trypsin, also cleave the bond between amino acids 16 and 17, and the effect should be attributed to thrombin or a thrombin-like enzyme. The results listed in Tables VI and VII indicate a lack of correlation between FPA and fibrinogen-fibrin degradation product levels, and in several patients FPA levels were elevated although the degradation product levels were normal.
Another question concerns the significance of the disappearance rate noted in Fig. 4 normal subjects the initial clearance rate is consistent with a ti of 3-5 min. The clearance rate may be different in patients with diminished renal function or other disease states. At levels below about 2 ng/ml, it was not clear that the same clearance rate obtains. In patients with thrombophlebitis, heparin infusion 'was followed by a prompt drop in fibrinopeptide level at a rate consistent with a 3-5-mitn. Basing calculations on a 3-5-min tl, one may calculate that when the FPA level is 0.5 ng/ml, a production rate is implied of 0.5 ng/ml/3-5 min or 0.36-0.6 mg/24 h for an individual with a 2.5-liter plasma volume. Such a production rate could be produced by thrombin proteolysis of 40-67 mg of fibrinogen per 24 h, which would represent about 2-3% of the normal total fibrinogen catabolism of 2.2 g/24 h in a 70-kg individual (24) . These figures are consistent with previously held views that in normal individuals thrombin proteolysis is not a major determinant of fibrinogen catabolism (25) . A question that arises about the FPA levels found in normal individuals is whether they represent a state of continuous intravascular thrombin action (26, 27) . It is not possible to make a definite interpretation of the results, since heparin infusion in normals did not render the A peptide level undetectable. Further work is required to distinguish amongst various possible explanations for the failure of a single heparin infusion to lower the FPA level to an undetectable level. It is possible that the 0.15 ng/ml difference between the pre-and post-heparin levels is nearer the true normal level than the 0.5 ng/ml mean normal level found in the 30 normal men tested. Such a level would be produced by proteolysis of 12-20 mg fibrinogen/24 h, representing 0.5-1% of normal total fibrinogen catabolism per day. A 10 ng/ml FPA level would imply a proteolysis rate of about 0.8-1.3 g fibrinogen/24 h.
All such calculations at present are hypothetical, and their validity must be tested by comparative studies of fibrinopeptide levels and fibrinogen metabolism.
The elevated FPA levels found in patients in whom conventional tests indicate the presence of "defibrination syndrome" or "diffuse intravascular coagulation" were not surprising. The results do not prove the existence of excessive thrombin action in vivo, although that is the favored explanation. The action of other thrombin-like enzymes is not excluded. One of the most provocative results has been the finding of elevated FPA levels in several patients with thrombophlebitis and pulmonary embolism. Further studies will be required to establish the relative frequency and specificity of the elevated FPA levels in relation to pulmonary embolism and venous thrombosis. The possibility that FPA measurements could be used to monitor the influence of physiological circumstances and the therapeutic effectiveness of phar-52 macological agents is one of the most promising arising from the present studies.
